SCHEMBL16666329

SCHEMBL16666329

O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(O)=S)c1ccc(Cl)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UBASH3B Q8TF42 1/20 0.84
▸ F11 P03951 3/20 0.53
▸ TACR1 P25103 3/20 0.51
▸ CCKBR P32239 1/20 0.50
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ PPARG P37231 1/20 0.47
▸ ITGB2 P05107 2/20 0.46
▸ ICAM1 P05362 2/20 0.46
▸ ITGAL P20701 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ ERAP2 Q6P179 1/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC7 Q8WUI4 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ HDAC10 Q969S8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29868911 1.00 UBASH3B (0.84) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL5794018 0.92 UBASH3B (1.00) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL29560992 0.92 UBASH3B (1.00) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL221527 0.92 UBASH3B (1.00) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL21623658 0.92 UBASH3B (1.00) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL23346201 0.92 UBASH3B (1.00) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL2292009 0.91 UBASH3B (0.98) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL28798513 0.91 UBASH3B (0.98) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL9114879 0.91 UBASH3B (0.98) UBASH3BF11TACR1CCKBRKMT2A
Rebamipide SCHEMBL28341360 0.91 UBASH3B (0.98) UBASH3BF11TACR1CCKBRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865669-B1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF SAMJIN PHARM CO LTD (KR) 2021-04-28 — — EP claimed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US claimed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP claimed
US-11420963-B2 Rebamipide prodrugs, preparation method and use thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2022-08-23 — — US disclosed
EP-2865669-B1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF SAMJIN PHARM CO LTD (KR) 2021-04-28 — — EP disclosed
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF ASTECH. CO., LTD. (KR) 2015-05-21 — — US disclosed
EP-2865669-A1 NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2015-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141409-A1 NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF REV1, GRPR, SI UBASH3B 2690/4885F11 1844/4885TACR1 2155/4885
US-11420963-B2 Rebamipide prodrugs, preparation method and use thereof SI, CYP2A7, MLN UBASH3B 3043/4885F11 1326/4885TACR1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback